Evidence map›Paper›PMID 32206972›Full record

ArticleClinical rheumatology2020

Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren's syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis.

Nevin Hammam, Nada M Gamal, Mona H Elzohri, Amira M Elsonbaty, Ahmed M Rashed, Zeiad H Eldaly, Dalia Tarik, Tamer A Gheita

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nevin HammamRheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut Campus, Assiut, Egypt. Nevin.Hammam@ucsf.edu.ORCID https://orcid.org/0000-0002-7754-5581
Nada M GamalRheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut Campus, Assiut, Egypt.
Mona H ElzohriDepartment of Internal Medicine, Rheumatology & Clinical Immunology Unit, Assiut University Hospitals, Assiut, Egypt.
Amira M ElsonbatyRheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut Campus, Assiut, Egypt.
Ahmed M RashedRheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut Campus, Assiut, Egypt.
Zeiad H EldalyDepartment of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Dalia TarikClinical Pathology Department, Assiut University Hospitals, Assiut, Egypt.
Tamer A GheitaRheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Assiut University Hospitals · EGAssiut University · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

objectivesSystemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) may coexist and carry a higher risk for future comorbidities. Although 14-3-3η protein is recently a known diagnostic marker in rheumatoid arthritis (RA), its role has not been investigated in SLE. The aim of this study was to compare serum 14-3-3η protein level in SLE and RA patients and to examine its association with clinical and laboratory features in SLE patients.

methodsEighty-four SLE patients and 39 RA patients were included. Sociodemographic, SLE disease activity index (SLEDAI), and damage index were assessed for SLE patients. Data about secondary SS were collected. 14-3-3η was measured by ELISA; titres above 0.19 ng/ml were considered positive.

resultsSerum 14-3-3η protein in SLE was significantly lower than in RA (0.37 ± 0.09 vs 1.5 ± 0.51; p < 0.001). 14-3-3η protein level was comparable between SLE patients with and without arthritis (0.29 ± 0.8 vs 0.15 ± 0.08 respectively; p = 0.20). Serum 14-3-3η protein level was higher in SLE with secondary SS features compared to those without (0.22 ± 0.10 IU/ml vs 0.11 ± 0.04 IU/ml; respectively, p < 0.001). There were no differences in 14-3-3η positivity for other lupus criteria or correlation of 14-3-3η titer with SLEDAI. 14-3-3η protein at 1.11 ng/mL yield a secondary SS diagnostic accuracy of 71%.

conclusionsSerum 14-3-3η protein level is high in SLE-associated SS. The 14-3-3η protein level was able to distinguish patients with secondary SS among patients with SLE. Studying the role of 14-3-3η protein in Sjögren's syndrome would be considered in further larger scale studies to confirm the impact of any association. Key Points • Serum 14-3-3η protein level is significantly higher in systemic lupus patients with secondary Sjögren's syndrome (SS) in comparison to those without. • Serum 14-3-3η protein can be used as a useful marker to distinguish patients with secondary SS among patients with systemic lupus. • 14-3-3η protein level shows no difference between systemic lupus patients with and without arthritis.

Indexed as

Arthritis, RheumatoidLupus Erythematosus, SystemicSjogren's Syndrome14-3-3 ProteinsCross-Sectional StudiesHumans14-3-3 Proteins14-3-3η proteinArthritisSjögren’s syndromeSystemic lupus erythematosus

Identifiers

PMID32206972
OpenAlexW3012690536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.